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Abstract
Anemia is frequent among brain-injured patients, where it has been associated with an increased risk of poor
outcome. The pathophysiology of anemia in this patient population remains multifactorial; moreover, whether
anemia merely reflects a higher severity of the underlying disease or is a significant determinant of the neurological
recovery of such patients remains unclear. Interestingly, the effects of red blood cell transfusions (RBCT) in
moderately anemic patients remain controversial; although hemoglobin levels are increased, different studies
observed only a modest and inconsistent improvement in cerebral oxygenation after RBCT and raised serious
concerns about the risk of increased complications. Thus, considering this "blood transfusion anemia paradox",
the optimal hemoglobin level to trigger RBCT in brain-injured patients has not been defined yet; also, there is
insufficient evidence to provide strong recommendations regarding which hemoglobin level to target and which
associated transfusion strategy (restrictive versus liberal) to select in this patient population. We summarize in
this review article the more relevant studies evaluating the effects of anemia and RBCT in patients with an acute
neurological condition; also, we propose some potential strategies to optimize transfusion management in such
patients.
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Background
Anemia is a frequent condition among critically ill pa-
tients [1] and appears early during their hospital course.
In a European, multicenter study on 3534 patients, 63 %
of those newly admitted to the intensive care unit (ICU)
had hemoglobin (Hb) levels below 12 g/dl on admission;
in particular, 29 % of them had Hb values below 10 g/dl
[2]. Overall, 37 % of these 3534 patients received at least
one red blood cell transfusion (RBCT) during their ICU
stay. Interestingly, during the first 28 days, Hb levels
tended to reach 10 g/dl on average regardless of the
initial Hb value or the occurrence of bleeding events. In
another study on 4892 ICU patients in which 44 %
received at least one RBCT after a median of 3 days,
an Hb level below 9 g/dl was associated with poorer
outcomes whereas the amount of RBCT transfused
was also associated with increased ICU length of stay and
mortality [3].
The pathophysiology of anemia in critically ill patients
remains multifactorial and has been compared to the
so-called “anemia of chronic illness”; as such, apart
from evident causes such as primary blood losses (e.g.,
trauma, surgery, gastrointestinal bleeding), multiple other
etiologies contribute and often coexist in the same patient
[4]. These include, amongst others, blood losses related to
minor procedures or phlebotomy, hemodilution secondary
to fluid resuscitation, altered red blood cell (RBC) produc-
tion, and reduced RBC half-life [5–7].
Although it is associated with poor outcome, whether
anemia exerts deleterious consequences on brain function
in various pathological conditions remains a matter of
debate. In neurological circumstances such as severe trau-
matic brain injury (TBI) or stroke, Hb level is a primary
determinant of brain oxygenation and, in a recent study,
anemia was an independent predictor of mortality among
patients suffering from an acute ischemic stroke [8, 9].
In this article, we summarize the literature evaluating
the effects of anemia and RBCT in patients with an acute
neurological condition as well as potential strategies to
optimize Hb management in such patients.
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Effects of anemia on the brain
Oxygen delivery (DO2) to the brain is directly propor-
tional to cerebral blood flow (CBF) and arterial oxygen
content (CaO2) and, therefore, also to Hb levels according
to the equation:
DO2 ¼ Q  CaO2
where Q indicates blood flow and CaO2 =Hb × SaO2 ×
1.39 (SaO2 indicates arterial oxygen saturation). According
to this equation, a significant reduction of Hb may lead to
decreased brain DO2 and eventually tissue hypoxia if the
compensatory mechanisms aiming to keep a constant tis-
sue oxygenation fail or are overtaken [10]. In the setting of
normovolemic anemia, these mechanisms include the ac-
tivation of carotid and aortic chemoreceptors and, hence,
of the sympathetic tone, which lead to a rise in heart rate
and left ventricular stroke volume, resulting in increased
cardiac output and CBF [11]. Oxygen extraction is also in-
creased at the microcirculatory level [12]. Moreover,
anemia is associated with reduced blood viscosity, which
promotes venous return and decreases the resistance to
systemic flow as well as reduces endothelial shear stress,
resulting in an improved microvascular perfusion [13, 14].
In this setting, cerebral vasodilation is promoted by
enhanced production of nitric oxide (NO) by perivascu-
lar neurons and endothelial cells [15]. This results in an
increased CBF that maintains a constant cerebral DO2.
Importantly, according to Poiseuille's equation showing
that blood flow is proportional to the vessel radius to
the fourth power, small changes in vascular diameter will
have a large influence on CBF. The role of NO in regu-
lating CBF during anemia is extremely complex: cerebral
hypoxic vasodilatation can be altered by NO synthase
(NOS) inhibitors through a direct effect on neuronal
NOS (nNOS) [15], while expression of endothelial NO
synthase (eNOS) is increased by increased capillary shear
stress [16]. Finally, oxyhemoglobin is also able to trans-
port NO; following oxygen release from oxyhemoglobin,
structural changes in heme conformation could promote
NO release and further promote local vasodilation in
territories with high oxygen extraction [10]. Interestingly,
cerebral hypoxia secondary to severe anemia would also
induce the production of the transcription factor hypoxia-
inducible factor (HIF), an heterodimer composed of two
subunits (HIF-1α and HIF-1β) which plays an important
role in the protection of brain cells from ischemia [17].
Moreover, HIF also promotes the secretion of erythro-
poietin (EPO), which negatively regulates neuronal
apoptosis and seems to exert some neuroprotective
effects through specific receptors expressed within cere-
bral tissue [18], and of vascular endothelial growth factor,
which stimulates angiogenesis and allows long-term adap-
tations to tissue hypoxia [19].
Overall, these adaptation mechanisms maintain DO2
during anemia in healthy conditions, at least until a
critical Hb threshold below which tissue hypoxia and
altered brain function may develop. As such, in healthy
volunteers submitted to progressive normovolemic
anemia, some authors observed increasing fatigue and
cognitive disorders (short- and long-term memory dis-
turbances) when Hb levels fell to 5 g/dl; these symptoms
were rapidly reversed after autologous RBCT [14, 20]. In
healthy subjects, however, acute normovolemic anemia
(to Hb levels of 5.1 ± 0.3 g/dl) was not associated with
increased somatosensory-evoked potential latencies, sug-
gesting brain dysfunction [21]. These findings underline
that a progressive reduction of Hb in the normal brain
can be compensated by an increase in CBF due to cerebral
vasodilation until a critical Hb level around 5–6 g/dl, when
cerebral DO2 will be progressively reduced as no further
vasodilation can occur and maximal CBF values are ob-
tained (Fig. 1). Nevertheless, these data on healthy volun-
teers may not directly translate to brain-injured patients.
First, Hb levels in these critically ill patients are generally
higher than those used in the aforementioned studies [22].
Second, some of these brain-injured patients may develop
hemodynamic instability or acute heart failure, which
would significantly impair the compensatory increase in
cardiac output to provide adequate cerebral oxygenation
during anemia [23]. Third, anemia-induced vasodilation
may be limited by other ongoing compensatory mecha-
nisms to maintain adequate brain perfusion induced by the
acute brain injury itself, so that the “cerebrovascular re-
serve”, i.e., the capability of brain vasculature to vasodilate
in response to different stimuli (including changes in mean
arterial pressure, arterial carbon dioxide tension (PaCO2),
or reduced DO2), is significantly limited when compared
with healthy subjects [24]. This could promote brain tissue
hypoxia at hemoglobin levels higher than the hemoglobin
thresholds observed in healthy volunteers [25]. Finally,
brain lesions observed after TBI or a stroke may be highly
heterogeneous; some territories defined as "penumbra"
zones (e.g., moderately ischemic tissue lying between tissue
that is normally perfused and an infarcted area) exist,
where oxygen supply may become inadequate to satisfy
oxygen demand in the case of anemia. Thus, in the injured
brain, a lower CBF compared with the normal brain is
observed for similar Hb values (Fig. 2). As the “cerebro-
vascular reserve” is compromised in this setting, maximal
vasodilation may occur at Hb levels around 8–9 g/dl and
any further decrease in Hb below this threshold may
contribute to reduced cerebral DO2.
Effects of anemia on the injured brain
Traumatic brain injury
Several studies have shown an association between
anemia and poor outcome after TBI [26–28]. In two
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post hoc analyses including more than 3500 patients
with severe TBI (defined as a Glasgow Coma Scale
score <9), low Hb levels were significantly associated
in a logistic regression model with poor neurological
outcome at 3 and 6 months after the initial insult [28, 29].
In a retrospective study on 1150 patients with TBI, anemia
(defined as an Hb level below 9 g/dl) was significantly
associated with increased mortality (adjusted odds ratio
(OR) 3.67, 95 % confidence interval (CI) 1.13–2.24) [26].
In another retrospective study on 169 patients with TBI,
an average Hb level below 9 g/dl over a period of 7 days
was associated, in a multivariate analysis, with increased
Fig. 1 In the normal brain, a progressive reduction of hemoglobin (Hb) is compensated for by vasodilation, which results in increased cerebral
blood flow (CBF, black line) and a constant cerebral oxygen delivery (DO2, grey line). When Hb falls below 5–6 g/dl, DO2 is progressively reduced;
no further vasodilation can occur and maximal CBF values (CBFmax) are obtained. The oxygen extraction rate (OER) then increases to meet
metabolic tissue requirements
Fig. 2 In the injured brain, cerebral blood flow (CBF, black line) is lower than in the normal brain at the corresponding Hb levels. As the
“cerebrovascular reserve” is compromised in this setting, the maximal CBF (CBFmax) will be possibly obtained at Hb levels around 8–9 g/dl and
any further decrease of Hb below these thresholds will contribute to reduce cerebral oxygen delivery (DO2, grey line). The oxygen extraction rate
(OER) then increases to meet metabolic tissue requirements above these thresholds
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hospital mortality (relative risk 3.1, 95 % CI 1.5–6.3; p =
0.03) [27]. Similar observations were found in two other
studies [30, 31], although the evaluation of anemia and
poor outcome after TBI did not consistently demonstrate
harm in others [32–34]. Unfortunately, these studies gen-
erally had important methodological weaknesses. Most of
them were retrospective, which may have reduced the
collection of variables potentially influencing outcome.
Also, anemia was defined according to different cutoffs,
thus limiting comparison among all the different cohorts
of patients. Also, only one single Hb measurement was
considered in the definition of anemia, while the exposure
of an injured brain to prolonged periods of low Hb levels
may be more relevant. As an example, in 116 patients with
severe TBI, Griesdale et al. [35] observed that a Hb time
curve above 9 g/dl was associated with improved neuro-
logical outcome independent of the administration of
RBCT. Finally, the primary outcome evaluating the rela-
tionship between anemia and outcome was mortality in
some studies while others focused on long-term neuro-
logical recovery [36].
Furthermore, anemia has also been associated with
changes in brain metabolism or oxygenation. As such,
Sahuquillo et al. [37] showed that, in 28 patients with se-
vere TBI, low Hb levels were one of the most important
predictors of the development of ischemic areas, as sug-
gested by increased arterio-jugular oxygen (AJDO2) and
lactate differences. Similarly, Cruz et al. [38] evaluated the
cerebral metabolic rate of oxygen consumption (CMRO2)
in TBI patients with anemia and found that a decrease of
Hb was associated with a decrease in CMRO2 independ-
ent of the level of consciousness of patients. However,
anemia (defined as Hb <11 g/dl in at least three measure-
ments) was associated with a marked decrease in AJDO2
in only 9 % of the observations in another study [39], sug-
gesting that global cerebral ischemia is a rare finding in
acute brain injury with anemia. More recently, in a retro-
spective analysis of 474 simultaneous measures of Hb and
brain oxygen tension (PbtO2) in 80 TBI patients, only Hb
levels <9 g/dl were significantly associated with a low
value of PbtO2 (<20 mmHg). In this study, anemia com-
bined with low PbtO2 was associated with poor neuro-
logical outcome (Glasgow Outcome Scale of 1–3 at
30 days), whereas isolated anemia was not [40]. Associ-
ation between anemia and low PbtO2 was, however, not
found in all studies [41].
Subarachnoid hemorrhage
In several studies including patients suffering from sub-
arachnoid hemorrhage (SAH), anemia was an independ-
ent risk factor for poor neurological outcome [42, 43]. In
a retrospective study on 580 patients with SAH, anemia
was an independent risk factor for mortality and neuro-
logical disability at 3 months, even after correction for
confounders (OR 1.8, 95 % CI 1.1–2.9, p = 0.02) [44]. In
another retrospective study (n = 245), Hb below 10 g/dl
was associated with poorer outcomes, including mortality,
severe disability, and the development of delayed cerebral
ischemia [45]. Conversely, in a large cohort of SAH pa-
tients (n = 611), higher Hb levels were found in patients
with good outcome compared with those with poor out-
come (11.7 ± 1.5 versus 10.9 ± 1.2 g/dl, p < 0.001) [46];
also, the highest Hb values over the ICU stay were an
independent predictor of good neurological recovery at
3 months.
As for studies on TBI, the effects of anemia on brain
metabolism have also been evaluated in SAH patients. In
a prospective study on 20 patients with poor-grade SAH,
Hb levels below 9 g/dl were associated with an increased
risk of low PbtO2 values (<20 mmHg) and altered metab-
olism (e.g., increased lactate to pyruvate ratio (LPR) above
40 when assessed using cerebral microdialysis catheters),
suggesting ongoing anaerobiosis in the absence of ad-
equate cerebral DO2 [47]. Also, in a retrospective analysis
of 359 different measurements performed in 34 SAH
patients, Hb levels below 9–10 g/dl were independent
predictors of tissue hypoxia (e.g., elevated LPR) compared
with higher Hb levels [48].
Other forms of brain injury
Anemia on admission has been found to be among the
most significant predictors of short- and long-term poor
outcome in patients with acute ischemic stroke [49]. In
young patients suffering from acute stroke due to cer-
vical artery dissection (n = 1206), anemia (defined as
Hb <12 g/dl) was found in 7 % of them on admission
and was associated with the severity of stroke and un-
favorable neurological outcome [50]. In another study,
anemia on admission (identified as an hematocrit value
less than 30 %) was associated with poor outcome in
patients with less severe stroke, defined as a National
Institutes of Health Stroke Scale score of <10 [51]. Never-
theless, mild anemia could worsen patients’ functional
status also when occurring in the sub-acute phase of
stroke [52]. Also, decreasing Hb levels after admission
could independently predict infarct growth in stroke
patients treated with intravenous thrombolysis [53]. In
contrast, in a recent retrospective study, Hb concentra-
tions higher than the normal limits on admission were
also associated with greater disability at discharge and
30-day mortality, even after adjustment for major po-
tential confounders, after ischemic stroke [54].
In one retrospective study, anemia on admission was
identified in 19 % of patients with a non-traumatic intra-
cranial hemorrhage (ICH) and was found to be an inde-
pendent predictor of long-term mortality [55]. Also, lower
Hb levels (<12 g/dl) were found in 23 % of 2406 ICH
patients during their hospital stay, including 4 % with
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Hb <10 g/dl [56]. Patients with anemia were more likely
to have severe neurological deficits on admission, in
particular when ICH was not associated with the use of
anticoagulants. Hb below 10 g/dl was also associated with
poor outcome and increased 1-year mortality. Similar
results were also found in other studies [57, 58]. Interest-
ingly, anemia was also a predictor of larger hematoma
volumes in these patients [59].
Among patients suffering from post-anoxic brain in-
jury, Ameloot et al. [60] found a strong linear relation-
ship between Hb and cerebral brain oxygen saturation
(StO2), assessed by non-invasive near-infrared spectros-
copy. Moreover, Hb levels below 10 g/dl generally resulted
in low StO2 values, while Hb values above 12.3 g/dl were
associated with better outcome, particularly in patients
with StO2 values <62 %.
Efficacy of RBCT in patients with acute brain injury
Considering the frequent association of anemia and poor
outcome after an acute brain injury, current recommen-
dations on the use of a restrictive transfusion strategy in
ICU patients (transfusion if Hb levels <7 g/dl in the
absence of severe cardiac comorbidities) [61] may not
apply to patients with brain injuries. One may argue that
RBCT to increase Hb levels above 9–10 g/dl in these pa-
tients would be a logical therapeutic decision to reduce
the risk of tissue hypoxia and potentially improve patient
outcome. Nevertheless, the benefits of RBCT should
always be weighed against the risk of a transfusion-
related complication; as such, RBCT was associated with
increased mortality and a higher occurrence of organ
dysfunction among critically ill patients, although this
has been observed only in observational studies [62].
The pathophysiology of such complications is complex
and is related to several pathways, including immune
modulation [63], risk of circulatory overload [64] or acute
lung injury [65], altered RBC function due to prolonged
storage [66], or impaired peripheral microcirculation due
to NO scavenging and reduced deformability [67].
Severe traumatic brain injury
In some recent studies on patients with severe TBI, the in-
crease in PbtO2 after RBCT was generally small [68–71];
moreover, RBCT was associated with a decreased PbtO2
in some subjects. These studies included no clear predic-
tion criteria to distinguish between "responders" and
"non-responders" (on the basis of PbtO2 changes) to
RBCT [69, 71]. Even if RBCT could produce an improve-
ment in cerebral oxygenation, this was not always accom-
panied by significant changes in cerebral metabolism, e.g.,
reduction in LPR [71].
Alternatively, studies evaluating RBCT as a predictor
of good outcome after TBI have found inconsistent re-
sults, although some of them suggested detrimental effects
[43]. In a large retrospective study on 1150 TBI patients in
which 46 % of patients received RBCT when Hb levels
were below 9 g/dl, Salim et al. [26] found that RBCT was
associated with an increased hospital mortality in a logistic
regression model (adjusted OR 2.19, 95 % CI 1.27–3.75,
p = 0.004), while anemia was not. In another retro-
spective study on 139 anemic patients (hematocrit be-
tween 21 and 30 %) with TBI, RBCT was an independent
risk factor for poor neurological outcome at 3 and
6 months [70]. Other studies did not confirm these find-
ings. In a small retrospective study of 82 TBI patients with
moderate anemia (Hb between 8 and 10 g/dl), there was
no association between RBCT and poor neurological out-
come and mortality was similar between anemic patients
(Hb between 8 and 10 g/dl) who received RBCT and those
who didn’t [68].
Subarachnoid hemorrhage
Several studies on patients with SAH found an associ-
ation between RBCT and worse neurological outcome or
even increased mortality [43, 72–74]. In a retrospective
study on 245 patients with SAH, RBCT was associated,
in a multivariate analysis, with an increased risk of
composite endpoint, including mortality, severe disabil-
ity, or delayed cerebral ischemia (OR 4.3, 95 % CI 1.5–9.3,
p < 0.01), as well as the occurrence of more nosocomial in-
fections [45]. However, these findings were not confirmed
in all studies. In a study on 292 SAH patients, the authors
found no association between RBCT and increased mor-
tality or poor neurological outcome in a multivariate
analysis [75].
Few studies have evaluated the impact of RBCT on
brain oxygenation in poor-grade SAH patients. In one
study on 35 neuro-critically ill patients (including 12
with SAH) receiving RBCT (2 units on average; mean
Hb threshold for RBCT of 8.7 g/dl), Smith et al. [69] ob-
served only a modest increase in PbtO2 (3.2 mmHg) and
no relationship between the increase in PbtO2 and base-
line values of cerebral oxygenation; importantly, in nine
patients, PbtO2 decreased after RBCT. In another study,
Kurtz et al. [76] showed that each 1.0 g/dl increase in
Hb levels after RBCT in poor-grade SAH patients was
associated with an increase in PbtO2 of 1.39 mmHg,
without significant effects on cerebral LPR. In a pro-
spective study on eight anemic SAH patients (baseline
hemoglobin 8.7 g/dl) in whom a cerebral positron emis-
sion tomography (PET) was performed, the administra-
tion of 1 unit of RBC resulted in a significant increase in
brain DO2; these effects were independent of CBF and
related to a higher CaO2 [77]. In this study, CMRO2
remained globally unchanged but there was a significant
decrease in oxygen extraction ratio, in particular in cere-
bral territories with the lowest baseline DO2. To confirm
that these data were not secondary to the hemodynamic
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effects (e.g., increased cardiac output or mean arterial
pressure through fluid expansion) of RBCT, the same
authors evaluated brain DO2 in three subgroups of
poor-grade SAH patients (nine receiving a fluid bolus,
12 receiving phenylephrine to raise mean arterial pres-
sure without clear vasospasm, 17 receiving one RBCT in
case of Hb <11 g/dl—baseline Hb of 9.1 ± 1.2 g/dl) [78].
Regional cerebral DO2 significantly increased in the
three groups but the effects were more important in
patients receiving RBCT; however, the proportion of pa-
tients with low DO2 was decreased only among patients
treated with vasopressors or RBCT, showing the more
relevant improvement in global cerebral oxygenation.
Other forms of brain injury
Outcomes in ICH patients receiving RBCT have been
contradictory. In 546 consecutive patients with ICH,
RBCT was administered to 100 patients (18 %) during
their hospital stay; in multivariable analysis, RBCT was
associated with improved survival at 30 days (OR 2.76,
95 % CI 1.45–5.26, p = 0.002) [79]. A recent retrospective
study failed to demonstrate an improvement in outcomes
with RBCT in patients with ICH [80]. Also, in another
study, RBCT was not an independent predictor of im-
proved neurological outcome [81].
Very few data are available on the effects of RBCT on
the outcome of patients with ischemic stroke. A recent
retrospective study showed that one-third of anemic
(Hb <12 g/dl) patients received at least one RBCT at the
discretion of the attending physician; although anemia
was associated with a longer length of ICU stay and dur-
ation of mechanical ventilation requirements, no signifi-
cant benefit from RBCT was found and no specific
transfusion strategies were recommended in this patient
population [82].
Which is the optimal transfusion strategy for patients
with acute brain injury?
Only a few studies have compared the effects of two dif-
ferent transfusion strategies on the outcome of patients
with an acute brain injury. In a subgroup analysis of the
multicenter randomized Transfusion Requirements in
Critical Care (TRICC) trial on 67 patients with TBI,
patients randomized to the “restrictive” RBCT policy
(e.g., Hb of 7.0 g/dl to initiate RBCT, n = 29) received
less RBC units than those included in the “liberal” strategy
(Hb of 10.0 g/dl to initiate RBCT, n = 38), with a similar
30-day mortality (17 versus 13 %, p = 0.64), hospital length
of stay, and development of multiple organ dysfunction
[32]. In the subgroup of 66 children with different types of
brain injury included in the Transfusion Requirements in
the Pediatric Intensive Care Unit (TRIPICU) study, pa-
tients were randomized to receive RBCT for an Hb
threshold of 7 or 9.5 g/dl [83]; the mortality rate was very
low (3/66) and similar between the two groups. In a retro-
spective study, TBI patients receiving RBCT and who
could not reach an Hb target of at least 9.3 g/dl at the end
of the initial surgery showed a higher early mortality than
others (17/37 (46 %) versus 34/102 (33 %)) [84]. After ad-
justment for confounders, however, no significant impact
of transfusions was found on patient outcome and the
difference in mortality was lost after 4 weeks. In two other
retrospective studies on TBI [68, 70] including more than
200 patients, patients receiving at least one RBCT were
compared with those who were not transfused for a spe-
cific range of Hb between 7 and 10 g/dl; no significant
effect on outcome was observed.
Only two prospective randomized trials have been
conducted specifically in brain-injured patients. In the
first study, Naidech et al. [85] randomized 44 SAH
patients at high risk of vasospasm to receive RBCT for a
target Hb of 10 or 11.5 g/dl; more transfusions were ob-
served in the high Hb threshold group than in the other,
while safety endpoints (e.g., infections and thrombo-
embolic events) were not different between the groups.
The numbers of cerebral infarctions on cerebral magnetic
resonance imaging (MRI; 6/20 versus 9/22) and of patients
showing a poor neurological recovery were lower, al-
though not statistically significant, in the higher Hb
threshold group. Nevertheless, the primary outcome of
this study was the safety of two different RBCT policies
and the limited cohort of patients precluded any further
analysis of the impact of Hb levels on neurological out-
come. In the second study, Robertson et al. [86] investi-
gated the effects of two different thresholds of Hb to
guide RBCT (7 versus 10 g/dl) in patients suffering from
TBI in a factorial design including also the administration
of erythropoietin (EPO) or placebo. On a total of 200
patients, favorable outcome (dichotomized Glasgow Out-
come Scale at 6 months) was similar between patients
included in the 7 g/dl (37/87, 43 %) or in the 10 g/dl (31/
94, 33 %) group , although patients maintained relatively
high median Hb levels in both groups throughout the
study (between 9.7 and 10.8 g/dl in the “restrictive” trans-
fusion strategy versus 11.0 and 11.5 g/dl in the “liberal”
strategy). This study showed that there was no significant
benefit in maintaining high Hb levels in patients suffering
from severe TBI. Moreover, thromboembolic events were
significantly more frequent in the group transfused at
10 g/dl (22/101 (22 %) versus 8/99 (8 %), p = 0.009).
Practices
Two surveys have been published to determine whether
physician specialty influences transfusion threshold in
patients with TBI or SAH. In the first study, trauma sur-
geons, neurosurgeons, and ICU physicians from 187
level I trauma centers in the United States were asked to
indicate their Hb threshold to initiate RBCT in two
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clinical scenarios referring to a patient with severe TBI
either with or without intracranial hypertension [87].
The response rate was 58 %; neurosurgeons used a
greater mean Hb threshold to initiate RBCT than trauma
surgeons and ICU physicians whether the intracranial
pressure was normal or elevated. Moreover, neuro-
surgeons used less indicators of poor anemia tolerance,
such as increased lactate, low mixed venous saturation, or
PbtO2, than the others to decide on RBCT. In a second
study conducted in North America, neuro-intensivists,
vascular neurosurgeons, and multidisciplinary intensivists
working in academic hospitals were questioned on the
common triggers to initiate RBCT in SAH patients [88].
More than half of the clinicians (282/531) eventually
responded. Mean Hb concentrations at which clinicians
administered RBCT significantly increased from a
good-grade SAH patient to a poor-grade one (7.8 versus
8.2 g/dl), in particular in the case of cerebral vasospasm
and delayed cerebral ischemia. Opinions covered a broad
range in each setting. Neurosurgeons expressed higher
minimum Hb goals than ICU physicians to initiate RBCT.
The presence of low PbtO2 (<15 mmHg) and high LPR
(>40) were also important triggers to administer RBCT.
A practical approach
Several observational studies have shown that anemia,
even if defined with different Hb thresholds, was associ-
ated with worse neurological outcome and increased
mortality rate after TBI, SAH, and other forms of brain
injury. Whether anemia merely reflects a higher severity
of the underlying disease, a longer ICU length of stay
and other ongoing processes (e.g., active bleeding, sepsis,
surgical procedures), or can directly affect the neuro-
logical recovery of such patients remains unclear. Inter-
estingly, the effects of transfusions to increase Hb levels
in moderately anemic patients remain controversial, with
a modest and inconsistent increase in brain oxygenation
after RBCT and serious concerns about the risk of in-
creased mortality. Thus, considering this "blood transfu-
sion anemia paradox", the optimal Hb level to trigger
RBCT in brain-injured patients has not yet been defined.
There is no strong evidence to support targeting a Hb
concentration greater than 7 g/dl or a liberal transfusion
strategy in this patient population. Importantly, it should
be better evaluated whether alternative strategies to RBCT
might be considered in this setting to avoid a significant
decrease of Hb levels below critical thresholds to ensure
adequate brain oxygenation.
According to what has been proposed for other critic-
ally ill patients, a “restrictive” transfusion practice should
be considered safe for brain-injured patients who are
awake and can undergo repeated clinical examination
(Fig. 3). In these patients, RBCT should be administered
to maintain Hb levels of at least 7.0 g/dl [89]. In case of
neurological deterioration or in poor-grade patients, the
decision to initiate RBCT should then be individualized
to some specific triggers suggesting a poor tolerance to
anemia (e.g., ischemic heart disease) or global/cerebral
tissue hypoxia, which may be secondary or at least
enhanced by reduced Hb levels. Regarding “systemic”
Fig. 3 The decision to administer red blood cell transfusions (RBCT) should take into consideration the potential benefits and harms of this
intervention, according to different haemoglobin (Hb) levels at which RBCT is initiated. In brain-injured patients, the RBCT strategy should be
“restrictive” (if Hb is less than 7.0 g/dl) in awake and conscious patients. For poor-grade comatose patients, systemic (superior vena cava oxygen
saturation (ScvO2) or high lactate levels) or cerebral triggers (jugular vein oxygen saturation (SvjO2) or brain tissue oxygen pressure (PbtO2)) could
be used to guide RBC administration
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triggers, optimization of oxygen delivery to reach a
mixed (SvO2) or superior vena cava (ScvO2) oxygen sat-
uration >70 % using, amongst all potential interventions,
also RBCT, as shown for the early management of sepsis
[90], may be useful to improve brain oxygenation and
overall outcome. As such, Gaieski et al. [91] showed that
early hemodynamic optimization of patients after post-
anoxic brain injury using a target ScvO2 of ≥65 % was
associated with reduced mortality, although not statisti-
cally significant, when compared with historical controls
(10/20 (50 %) versus14/18 (78 %), p = 0.15). Similarly,
Walters et al. [92] showed a trend towards better neuro-
logical outcome in patients treated with such a thera-
peutic approach compared with historical controls (31 %
versus 12 %, p = 0.08). Interestingly, RBC can signifi-
cantly influence the microcirculation, where their altered
morphology and deformability may impair local rheology
and further enhance microvascular abnormalities associ-
ated with sepsis, particularly in those patients with nor-
mal baseline microvascular flow [93]. Similar results
were also found for patients with elevated lactate levels
[94]. Thus, using biomarkers of impaired oxygen tissue
delivery could help to identify those patients who are
more likely to benefit from RBCT because of inadequate
systemic DO2, although no data are available on how
these systemic “triggers” can guide RBCT specifically in
brain-injured patients.
Specific “cerebral” triggers may be helpful and should
include the invasive or non-invasive assessment of cere-
bral oxygenation (e.g., venous saturation in the jugular
vein (SvjO2), PbtO2, or StO2) to individualize transfusion
requirements, even though they may suffer technical
limitations or poorly predict a “positive” response (e.g.,
improved oxygenation) to RBCT. Only patients with
anemia (e.g., Hb <9–10 g/dl) and concomitant tissue hyp-
oxia (e.g., PbtO2 <15–20 mmHg, SvjO2 <55 %) should be
considered as potential candidates for RBCT. The main
limitations of such an approach are that these
oxygenation-monitoring devices are not available in all
centers and some of them are costly and give information
only for a very limited area of the brain [88]; it would thus
be difficult to recommend the wide use of such tools in all
poor-grade brain-injured patients. Importantly, RBCT is
not the only therapeutic intervention that may improve
cerebral oxygenation in such patients; as such, clinicians
should rule out other possible causes for cerebral hypo-
perfusion (e.g., increased intracranial hypertension, severe
hypocapnia, systemic hypotension) or hypoxia (e.g., sei-
zures, hyperthermia, arterial hypoxemia) before consider-
ing RBCT in the management of such patients. Finally,
patients may present with signs of low systemic DO2 (e.g.,
low ScvO2) and normal cerebral oxygenation (e.g.,
PbtO2 > 20 mmHg). In this case, if the aim is to improve
cerebral DO2, cerebral triggers should be preferred to
target Hb levels in acute brain-injured patients, although
this strategy may result in systemic hypoperfusion and
non-cerebral organ dysfunction. Thus, decision to initiate
RBCT in brain-injured patients remains a critical chal-
lenge for clinicians in the absence of specific monitoring
tools.
Finally, future studies should also consider the use of
EPO and its derivates to slowly increase Hb and minimize
the risk of anemia and exposure to RBCT in such patients.
Moreover, EPO may exert dose-dependent neuroprotec-
tive actions, including anti-inflammatory, anti-apoptotic,
and endothelial effects, when administered in the early
phase after injury, at least in experimental models [95, 96].
In the human setting, a small retrospective study showed
some potential benefits for erythropoiesis-stimulating
agents after TBI [97], while significant concerns about the
increased risk of thrombotic events or even mortality have
been raised in patients with stroke or polytrauma [98, 99].
In a recent trial, Robertson et al. [86] showed no signifi-
cant benefits on neurological recovery of EPO compared
with placebo in 200 severe TBI patients. In another ran-
domized study, Nichol et al. [100] showed that EPO given
once per week for a maximum of three doses (n = 308) did
not reduce the proportion of patients with poor neu-
rological outcome compared with placebo (n = 298, 44
versus 45 %, p = 0.90). Unfortunately, the RBCT require-
ment was similar between groups, although the amount of
RBC packs transfused over the study period was not spe-
cifically reported in this study.
Conclusions
Anemia is common among brain-injured patients and asso-
ciated with worse outcome. RBC transfusions may rapidly
increase Hb levels in such patients but are also associated
with poor outcome and complications. Few clinical studies
on the optimal transfusion strategy have been performed in
this setting and are biased by significant confounders. A
restrictive RBCT policy should be implemented in such
patients, in particular if they are awake and conscious,
unless poor tolerance to anemia (e.g. ischemic heart
disease) are present. An individualized transfusion strategy
is warranted in poor-grade patients, using different tools to
detect global/cerebral hypoxia, although the reliability of
such approach need to be adequately validated.
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